SlideShare uma empresa Scribd logo
1 de 11
Baixar para ler offline
Diagnosis and Management of Dyslipidemia
            for Adults 18 Years of Age




The Clinical Practice Guidelines for the Diagnosis and Management of Dyslipidemia for
Adults 18 Years of Age was reviewed and approved by Unity’s Clinical Quality
Improvement Committee (CQIC) on May 16, 2008. The guideline was previously approved
by CQIC on November 18, 2005, September 17, 2004, September 11, 2003, September
10, 2001, March 5, 2001, and June 29, 1999. The UW Medical Foundation, UW
Hospitals and Clinics, Meriter Hospital, Unity Health Insurance, Physicians Plus
Insurance Corporation, and Group Health Cooperative participated in the development
and revision of this guideline. The task force was a multidisciplinary work group
comprised of physicians, pharmacists, a nurse practitioner and a nutritionist.
2008 GUIDELINE FOR THE DIAGNOSIS
                                                AND MANAGEMENT OF DYSLIPIDEMIA
                                                  FOR ADULTS > 18 YEARS OF AGE

This clinical guideline is designed to assist clinicians by providing a framework for the evaluation and treatment of patients
with or at risk for dyslipidemia. It is not intended to replace a clinician's judgement or to establish a protocol for the
treatment of a particular condition. A guideline rarely will establish the only approach to a problem.

                                                                                      CONTENTS

1. Treatment Overview of Dyslipidemia...................................................................................................................................2
2. Major CHD Risk Factors (Exclusive of LDL-C) ....................................................................................................................2
3. Screening Guidelines ..........................................................................................................................................................3
4. Lipid Treatment Goals and Cutpoints ..................................................................................................................................3
5. General Treatment Sequence Recommendations................................................................................................................4
6. Medication-Specific Treatment Recommendations .............................................................................................................6
7. Dose Equivalence Approximations ......................................................................................................................................7
8. Profiles of Major Medication Classes..................................................................................................................................7
9. Follow-up Evaluation and Maintenance Therapy .................................................................................................................8
10. Dyslipidemia Medications .................................................................................................................................................9
11. Resources .........................................................................................................................................................................9
12. References ......................................................................................................................................................................10
13. Acknowledgements & Disclosures .................................................................................................................................10




             2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults ≥ 18 Years Old - May 2008 - Page 1
             UM13973-1107P
Treatment Overview of Dyslipidemia
Dyslipidemia is a powerful risk factor for coronary heart disease (CHD). Clinical trials conclusively have demonstrated that
treatment of lipid disorders can reduce CHD morbidity and mortality. Treatment of lipid disorders also helps prevent stroke
and peripheral arterial disease.

1.  asic principle. The intensity of risk-reduction therapy should be based on the patient’s risk of a CHD event.
   B
   Patients with established CHD have a 10-year risk of having a CHD event (cardiac death or myocardial infarction) that is
    20% ( 2%/year). Accordingly, primary prevention patients with a similar risk (“CHD Risk Equivalent”) should be treated
   as aggressively. Such patients include those with non-coronary atherosclerosis (cerebrovascular disease, peripheral vas-
   cular disease, abdominal aortic aneurysm), type 2 diabetes mellitus, or an estimated 10-year CHD risk  20% using the
   Framingham risk factor equation. Similarly, the CHD risk of patients with extreme lipid abnormalities such as low-density
   lipoprotein cholesterol (LDL-C)  190, high-density lipoprotein cholesterol (HDL-C)  40, or triglycerides (TG) 500 mg/
   dL) qualify for aggressive treatment. These patients often have genetic disorders and their CHD risk is not reflected ade-
   quately by standard risk prediction techniques.

2.  ethods of risk assessment. Risk assessment is accomplished by a 2-step procedure. Count the number of major risk
   M
   factors3 (not including LDL-C). For persons with 2 or more risk factors, refine risk assessment using the Framingham
   risk factor equation. Easy to use, computerized and chart-based scoring tools to estimate 10-year risks of CHD events
   are available online at http://www.nhlbi.nih.gov/guidelines/cholesterol and at http://hin.nhlbi.nih.gov/atpiii/calculator.
   asp?usertype=prof.

    For screening and treatment, individuals can be categorized into five general risk categories:
          1. Very High –
          	  Recent acute coronary syndrome19
               •
          	 • CHD or non-coronary atherosclerotic vascular disease1 and one of the following:
               	    - Diabetes mellitus
               	    - Metabolic Syndrome8
          		        - Current smoking
          		        - Chronic kidney disease
	         2.  igh – CHD or CHD risk equivalent. Patients with extensive subclinical atherosclerosis, chronic kidney disease
             H
             and recipients of solid organ transplant are also at high risk.
	         3. Moderately High – No CHD with  2 risk factors and 10 yr CHD risk 10-20%
	         4. Moderate –No CHD with  2 risk factors and 10 yr CHD risk  10%
	         5. Lower – No CHD with  1 risk factor


    Major CHD Risk Factors (Exclusive of LDL-C)
3. n addition to high LDL-C, several factors increase the risk of CHD.
   I
	        • Current cigarette smoking
	        • Hypertension (blood pressure  140/90 mmHg or current treatment with antihypertensive medication)
	        • Low HDL-C ( 40 mg/dL)
	        • Family history of premature CHD (1st-degree relative: male  55 or female  65 years old)
	        • Age (male   45, female  55 years old)

Note: HDL-C  60 mg/dL can be considered a negative risk factor. Its presence may remove one risk factor from the count.




            2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults  18 Years Old - May 2008 – Page 2
Screening Guidelines
Screening Risk Group	                             Begin Screening	              Frequency	 Test
CHD, CHD risk equivalent, or  2 risk factors	 Age 20 years or at onset	 Yearly	                Fasting lipid panel
Familial dyslipidemia or family history of
premature CHD	                                 Age 20 years	             2 years	               Fasting lipid panel
None of the above 	                            Age 20 years	             5 years	               Fasting lipid panel or non-fasting
			                                                                                             total cholesterol and HDL-C4

4.  creening to determine the presence of atherosclerosis or risk factors can occur at any routine visit. If non-fasting
   S
   lipids are measured, obtain a fasting lipid profile if total cholesterol is  200 mg/dL or HDL-C is  40 mg/dL in a male
   or  50 mg/dL in a female.

5.  or rare patients with CHD or a CHD risk equivalent but no evidence of a dyslipidemia, re-screen every year
   F
   depending on presence of associated risk factors.


  L
   ipid Treatment Goals and Cutpoints
 Revised ATP III LDL-C goals based on recent clinical trial evidence
 Treatment Risk Group             Primary Target = LDL-C           Consider Medication               Secondary Target= Non-
                                                                   Therapy*                          HDL-C7(if TG  200)
 Very High2                       LDL-C  70                        70                               100
 High–CHD or CHD risk             LDL-C  100 ( 70   optional6)    100                             Non-HDL-C  130
 equivalent
 Moderately High–No CHD           LDL-C  130                       130                             Non-HDL-C  160
 with  2 risk factors and 10
 yr CHD risk 10-20%
 Moderate–No CHD with  2         LDL-C  130                       160                             Non-HDL-C  160
 risk factors and 10 yr CHD
 risk  10%
 Lower–No CHD with  1 risk       LDL-C  160                       190                             Non-HDL-C  190
 factor

*Based on health care providers judgement, it is optional to treat patients to the lipid targets at the next higher level of
RISK. For example, an LDL-C target of 70mg/dL is optional in all patients with CHD (see below). An LDL-C of 100 mg/dl is
an option in patients at moderately high risk.

6.  ptional target LDL-C  70 mg/dL. Option for anyone with CHD, but recommended for the following groups of CHD
     O
     patients:
     •
      Baseline LDL-C  100 mg/dL at time of diagnosis		           	       	
     • Acute coronary syndrome	         	        	
     • Diabetes mellitus	       	       	        	         	
     • Severe, poorly controlled risk factors, especially smoking	 	
     •  ultiple risk factors of Metabolic Syndrome8, especially TG  200 and HDL-C  40 mg/dL
       M
     • Chronic kidney disease

7.  on-HDL-C = total cholesterol minus HDL-C. When triglycerides are  200 mg/dL, LDL-C levels are measured less
   N
   accurately and may underestimate CHD risk. Therefore, for patients with elevated TG levels, treatment of the non-HDL-C
   level is a secondary target after the LDL-C target has been reached. The non-HDL-C level includes cholesterol carried in
   several atherogenic lipoproteins, such as LDL, very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL),
   and lipoprotein (a).




           2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults  18 Years Old - May 2008 – Page 3
8.  etabolic Syndrome. This is a common condition associated with increased CHD risk. Metabolic abnormalities include:
   M
   hyperinsulinemia often accompanied by glucose intolerance, abdominal obesity, hypertension, hyperuricemia, prothrombot-
   ic state, proinflammatory state, and the atherogenic lipoprotein phenotype (low HDL-C, hypertriglyceridemia, small dense
   LDL particles). Treatment of insulin resistance with exercise, weight loss and medications is a secondary target of therapy,
   in addition to lipid goals. The diagnosis of metabolic syndrome depends on the presence of three (3) or more of the follow-
   ing factors:
   	      • waist  40 for males, 35 for females (lower for Asian Americans:  35 for males, 31 for females; and for patients	
   	        with genetic disposition:  37 in males and 31 in females)		
   	      • fasting glucose  100 mg/dL
	         • TG  150 mg/dL			
	         • HDL-C  40 mg/dL males,  50 mg/dL females
	         •  lood pressure  130/85 mmHg or current treatment with antihypertensive medication
            b

9 T
 .  ype 2 diabetes mellitus and non-coronary atherosclerosis are CHD risk equivalents. Optimization of glycemic control may
    reduce TG. Use of metformin and pioglitazone may simplify the management of diabetic dyslipidemia because they raise
    HDL-C, lower TG levels, and reduce the number of small LDL particles.

10. Secondary causes of hyperlipidemia should be identified and treated:
	   	   • type 2 diabetes mellitus9	 	     	        • Metabolic Syndrome8 	            	         • hypothyroidism	
	   	   • obstructive liver disease	 	     	        • renal disease	 	                 	         • corticosteroid use
	   	   • progestin use	 	           	     	        • anabolic steroid use	            	         • alcohol use

11.  herapeutic Lifestyle Changes (TLC). These should be instituted in all patients if LDL-C or non HDL-C are above goal.
    T
    The TLC diet involves reduced intake of cholesterol-raising nutrients such as saturated and trans-fats, which should be
    restricted to  7% of calories. Dietary cholesterol is restricted to  200 mg per day. Additional LDL-C lowering options
    include 2 grams of plant stanol or sterols per day (fortified margines, yogurts, juices, etc.) and soluble fiber (3–6 g daily).
    Additional TG-lowering options include use of fish oil (omega-3 fatty acid) supplements (3-6 g daily). Weight reduction
    and increased physical activity are critical for the management of all dyslipidemias and to improve cardiovascular fitness.
    More information on TLC can be found within the NHBLI website at: http://rover2.nhlbi.nih.gov/chd/lifestyles.htm.


     General Treatment Sequence Recommendations
    Medication Sequence	                                               Lipid Pattern
	    TG  200 mg/dL	                      TG 200 – 499 mg/dL	                              TG  500 mg/dL
1st	 statin13	                            statin13 or niacin14	                            niacin14, fish oils or fibrate
2nd	 add niacin14, BAS17, or ezetimibe16	 statin + niacin14	                               combination of niacin14, fish oils or fibrate
3rd	 add niacin14, BAS17, or ezetimibe16	 add ezetimibe16	                                 add third TG-lowering medication, 	
			                                                                                        consider a statin

12.  eneral Principles of medication therapy. Medication therapy should be started if LDL-C or non-HDL-C are above target
    G
    values.
    For patients with CHD or CHD risk equivalent, medication therapy may be considered in combination with TLC at any time.
    Patients at high risk and very high risk should start medication therapy immediately. The decision to initiate medication
    treatment usually commits patients to lifelong therapy. In general, single medication therapy is initiated; however, the lipid-
    lowering effect is not directly proportional to the dose. A 30-40% LDL-C reduction should be targeted. Doubling a statin
    dose may decrease LDL-C by an additional 5% to 7%. Doses reaching or exceeding maximum daily doses have little or no
    benefit and increase the risk of side-effects. Combination therapy frequently will increase the likelihood of reaching lipid
    goals. TLC should be instituted prior to or concurrent with medication therapy. All patients with dyslipidemia should be
    referred for dietary counseling, preferably with a trained provider.

13.  he TG-lowering effects of statins are dose- and potency-dependent. As TG levels increase, higher doses of statins are
    T
    required. For moderate elevations of LDL-C in patients with elevated TG, prescription niacin (Niaspan)14 is an alternative.
    In general, statins should not be used alone in patients with TG 500 mg/dL.




             2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults  18 Years Old - May 2008 – Page 4
14.  he American Heart Association recommends use of a prescription niacin (Niaspan) rather than niacin supplements.
    T
    Supplements are not regulated and often contain more or less than the labeled amount of niacin, vary from lot to lot, and
    some are more hepatotoxic.

15. n general, the combination of statins and fibrates is discouraged. If this combination must be used, fenofibrate is safer
    I
    than gemfibrozil. If gemfibrozil is used, statin doses should be kept low. Be very cautious in older patients, those with
    kidney disease, and those on medications that affect statin metabolism.

16.  zetimibe inhibits intestinal cholesterol absorption. Statins are considered first line therapy for patients requiring
    E
    LDL-C reduction. Use ezetimibe in combination with statins for those patients unable to reach goal on highest tolerated
    dose of a statin. BAS and niacin also may be used. Ezetimibe reduces LDL-C by 17-23%. Ezetimibe is a first line agent only
    for patients with contraindications or medication intolerances to statins. This medicine has not been proven to reduce CHD
    events.

17.  ile acid sequestrants (BAS) can raise TG levels. If TG levels are elevated at follow-up, consider switching to Niaspan14.
    B

18.  mega-3 polyunsaturated fats (fish oils) at doses of 3-6 g/day lower TG levels by 30-50%. They should be administered
    O
    with meals. Prescription fish oil (Lovaza) is available. Most fish oil preparations that are available as dietary supplements
    are effective and also appear to be free of contaminants, but tend to be less potent. A non-prescription alternative that can
    be used is SUPER-EPA 2000. Fish oils are safe when used in combination with other lipid-lowering medications.

19.  cute MI patients. LDL-C and HDL-C levels may be artificially low due to inflammation during acute illnesses, such as
    A
    acute coronary or cerebral syndromes. Heparin also can decrease TG levels. If lipid levels are checked in hosptialized
    patients it should be recognized that they tend to underestimate ambulatory, usual lipid levels. For patients with acute syn-
    dromes, high-dose statin therapy (e.g., atorvastatin 80 mg/dL) should be initiated to target LDL-C (70 mg/dL). Rapid and
    aggressive reduction of LDL-C after an acute coronary syndrome improves clinical outcomes.

20.  ollowing LDL-C after an Acute Cardiac Event. For patients with an inpatient hospital stay for an acute cardiac event,
    F
    LDL-C should be checked at least one time between 42 and 365 days after discharge to assure the patient is at target.

21.  ow HDL-C. Low HDL-C is very common in persons with premature CHD, particularly males  45 and females  55
    L
    years old. A goal is to raise HDL-C as much as possible, by treating associated causes (hypertriglyceridemia, Metabolic
    Syndrome, physical inactivity, cigarette smoking, excessively high carbohydrate diets, etc). Achieving LDL-C and non-
    HDL-C targets and treatment of the Metabolic Syndrome are the dominant strategies. An isocaloric increase in dietary
    monounsaturated fats may help. For patients with isolated low HDL-C in whom medication therapy is appropriate, consider
    Niaspan 1000-2000 mg QHS, fish oils or fibrates in patients with elevated TG. Additional LDL-C lowering with a statin may
    be considered.

22.  en  35 years old and pre-menopausal women. The 10-year risk of CHD events is low unless they have severe risk
    M
    factors, such as familial hypercholesterolemia, cigarette smoking, or diabetes mellitus. Even though clinical CHD is uncom-
    mon, subclinical atherosclerosis can progress rapidly. Furthermore, CHD is a lifelong disease and risk factors in youth pre-
    dict premature CHD. TLC is the dominant strategy for young patients; however, medication therapy should be
    considered. Patients with extreme lipid abnormalities also should be treated aggressively.




           2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults  18 Years Old - May 2008 – Page 5
23. Medication-Specific Treatment Recommendations*
                                                             Very High2
 TG Level        RX Goal                   Start and maximize                                 Then add or switch to
  499           LDL-C  70                atorvastatin 40-80 mg, simvastatin 40-80 mg or     Add Niaspan 1000-2000 mg daily or BAS
                                           Vytorin 20-80/10 mg**
  500           LDL-C  70 and            Niaspan 2000 mg, omega-3 fish oils 4 g or          Add Niaspan, omega-3 fish oils, fenofibrate,
                 non-HDL-C  100           fenofibrate 200 mg                                 or statin
                                               High – CHD OR CHD Equivalent
 TG  200        LDL-C  100 (optional     If LDL-C  100, simvastatin 20-40 mg or lovas-     If patients don’t tolerate or reach goal on a
                  706)                    tatin 40 mg QHS. If LDL-C  130, simvastatin       high dose statin alone, add Niaspan 1000
                                           40 mg                                              mg-2000 mg QHS, ezetimibe, or BAS.	

 TG 200-499      LDL-C  100 and Non-      simvastatin 20-40 mg QHS                           Add Niaspan 1000-2000 mg QHS
                 HDL-C  130
 TG  500        LDL-C  100 and Non-      Niaspan 2000 mg QHS, omega-3 fish oils, or         Add Niaspan or omega-3 fish oils or fibrate
                 HDL-C 130                gemfibrozil 600 mg BID or fenofibrate 200 mg
                                           QD
     Moderately High/Moderate – Primary Prevention  2 Risk Factors and 10-year CHD Risk  20%
 TG  200        LDL-C  130               If LDL-C  130, simvastatin 20 mg or lovastatin  If patients don’t tolerate or reach goal on a
                                           40 mg QHS                                        high dose statin alone, add Niaspan 1000
                                           If LDL-C  160, simvastatin 20 – 40 mg or lovas- mg-2000 mg QHS, ezetimibe, or BAS.
                                           tatin 40-80 mg QHS
                                           If LDL-C  190, simvastatin 40 mg QHS
 TG 200-499      LDL-C  130 and Non-      simvastatin 20-40 mg                               Add Niaspan 1000-2000 mg QHS
                 HDL-C  160
 TG  500        LDL-C  130 and Non-      Niaspan 2000 mg QHS or omega-3 fish oils,          Add Niaspan or omega-3 fish oils or fibrate
                 HDL-C  160               gemfibrozil 600 mg BID or fenofibrate 200 mg
                                           QD
                                           Low – Primary Prevention  1 Risk Factor
 TG  200        LDL-C  160               If LDL-C  160, simvastatin 20 mg or lovastatin    If patients don’t tolerate or reach goal on a
                                           40 mg QHS                                          high dose statin alone, add Niaspan 1000
                                           If LDL-C  190 simvastatin 20-40 mg or lovasta-    mg-2000 mg QHS, ezetimibe, or BAS.
                                           tin 40-80 mg QHS
                                           If LDL-C  220, simvastatin 40 mg QHS
 TG 200-499      LDL-C  160 and Non-      simvastatin 20-40 mg or lovastatin 40-80 mg        Add Niaspan 1000-2000 mg QHS
                 HDL-C  190               QHS
 TG  500        LDL-C  160 and Non-      Niaspan 2000 mg QHS, omega-3 fish oils or          Add Niaspan, omega-3 fish oils or fibrate
                 HDL-C  190               gemfibrozil 600 mg BID or fenofibrate 200 mg
                                           QD

*  pecific treatment recommendations were made based on local HMO formulary coverages. These are subject to change at any time.
  S
  If switching to an alternative statin, use Table 24, below, for approximate equipotent dosing.
**This combination increases the chances of getting LDL-C to goal, but has not been proven to reduce cardiac events.
Consider referral to UW Health Preventative Cardiology Clinic for complicated patients with refractory dyslipidemia (requiring more than
2 medications to reach target), suspected genetic dyslipidemias, medication intolerances or patients with secondary causes.




            2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults  18 Years Old - May 2008 – Page 6
24. Dose Equivalence Approximations (for available strengths)
                       atorvastatin           fluvastatin              lovastatin              pravastatin            simvastatin         rosuvastatin            simvastatin/
                                                                                                                                                                  ezetimibe
                       ----                   20 mg                    10 mg                   10 mg                  5 mg                ----                    ----

 Approximate           5 mg                   40 mg                    20 mg                   20 mg                  10 mg               ----                    ----

 Equipotent            10 mg                  80 mg                    40 mg                   40 mg                  20 mg               5 mg                    ----

 Dose                  20 mg                  ----                     80 mg                   80 mg                  40 mg               10 mg                   10 mg/10 mg
                       40 mg                  ----                     ----                     ----                  80 mg               20 mg                   10 mg/20 mg
                       80 mg                  ----                       ----                   ----                  ----                40 mg                   10 mg/40 mg
                       ----                   ----                       ----                   ----                  ----                ----                    10 mg/80 mg

If changing statins, start on equivalent dose and recheck LDL-C levels and transaminases after 6-8 weeks.
Simvastatin, lovastatin, and atorvastatin are metabolized by the CYP3A4 system, a common metabolic pathway for many medications includ-
ing, but not limited to, protease inhibitors, azole antifungals, macrolide antibiotics and cyclosporine. Consider using other statins in patients
with renal insufficiency or patients on multiple medications with other medications metabolized by this isoenzyme system (such as verapamil,
diltiazem, or amiodarone).

 25. Profiles of Major Medication Classes
                       Statins                       Azetidinone                Nicotinic Acid            Omega-3                   Fibrates                Bile Acid
                                                                                                          Fish Oils                                         Sequestrants
 Medications           atorvastatin (Lipitor)        ezetimibe (Zetia)16        prescription niacin       Lovaza                    gemfibrozil             cholestyramine
                       fluvastatin                                              (Niaspan)14                                         fenofibrate             cholestyramine light
                       lovastatin                                               extended-release                                    (Lofibra, Tricor,       colesevelam
                       pravastatin                                              niacin/lovastatin                                   Antara)                 (Welchol)
                       rosuvastatin*(Crestor)                                   (Advicor)30
                       simvastatin                                              extended release
                                                                                niacin/simvastatin
                                                                                (Simcor)30
 Lipid Effects
   LDL-C               lower 18-60%                  lower 17-23%               lower 10-25%              may raise                 lower 5-20%             lower 15-30%
                                                                                                                                    (may raise)
   HDL-C               raise 5-15%                   raise 2%                   raise 15-35%              raise                     raise 10-20%            raise 3-5%
   TG                  lower 7-30%                   lower 4-11%                lower 20-50%              lower 30-50%              lower 20-50%            none or raise
 Major Use             elevated LDL-C, mild to       elevated LDL -C            moderately elevated       TG ≥ 500 mg/dl            TG  400 mg/dL          moderately elevated
                       moderately                                               LDL-C, elevated TG,                                                         LDL-C with normal
                       elevated TG, mildly low                                  low HDL-C                                                                   TG
                       HDL-C
 Contraindication      liver disease,                severe liver disease       liver disease,            none                      pregnancy28             bowel obstruction
 - Absolute            pregnancy28                                              pregnancy28
 - Relative            concomitant use                                          gout, hyperuricemia                                 liver or severe         TG  200 mg/dL
                       of fibric acid                                                                                               renal disease, gall-
                       derivatives27                                                                                                stones
 Long Term Safety      extensive clinical use,                                  3 years safety data for   10 years                  yes                     yes
                       10-yr safety data                                        Niaspan
 Major Side Effects    myopathy, myalgia,            well tolerated by          flushing29,               flatulence                dyspepsia, gall-        constipation,
                       abdominal pain, hepa-         most                       abdominal pain, gout,     indigestion               stone pain, hepato-     flatulence,
                       totoxicity                                               hyperglycemia, hepato-    burping                   toxicity                decreased medica-
                                                                                toxicity, ulcers                                                            tion
                                                                                                                                                            absorption
 Usual Daily Dose      see medication-specific       10 mg QD                   Niaspan29 1000-2000       4g QD                     G¶ = 600 mg BID         cholestyramine
                       treatment table23                                        mg QHS                                              L = 67-200 mg QD        4-16 g daily
                                                                                Advicor 500/20 mg-                                  T = 54-160 mg QD        colesevelam
                                                                                2000/40 mg                                                                  3750 mg daily
                                                                                Simcor 1000/20 mg-
                                                                                2000/40 mg

 Maximum Daily         see medication-specific       10 mg QD                   Niaspan 1000-2000 mg      4g QD                     G= 600 mg BID           cholestyramine
 Dose                  treatment table23                                        QHS                                                 L = 200 mg QD           24 g daily
                                                                                Advicor 2000/40 mg                                  T = 160 mg QD           colesevelam
                                                                                Simcor 2000/40 mg                                                           4375 mg daily
 LFT Monitoring27      0,2 then q 12 mos.            0,2, then q 12 mos         0,2,6 then q 12 mos.      none                      0,2,6 then q 12 mos.    none
 CPK monitoring27      muscle aches, pains,          none                       muscle aches, pains,      none                      muscle aches, pains,    none
                       tenderness                                               tenderness                                          tenderness
                                                                                                                                                           ¶G=gemfibrozil, L=Lofibra, T=Tricor

                 2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults  18 Years Old - May 2008 – Page 7
Follow up Evaluation and Maintenance Therapy
26.  asting lipid levels should be obtained 6-8 weeks following the initiation or alteration of therapy. For patients at goal, lipid
    F
    profiles should be performed annually.

27.  atients should be monitored for side effects of antilipidemic therapy as outlined in the medication profiles above. All
    P
    medications can cause transaminase elevation (incidence approximately 1%) and myopathy ( 0.1%). The risk is higher at
    the higher statin doses. If ALT or AST  3x normal or if the patient develops myopathy with an elevated CPK-MM fraction,
    the antilipidemic agent dose should be reduced, the agent should be changed, or the patient referred for further evaluation
    by a lipid management specialist. Transaminase should be repeated to assess progression or resolution.

28.  regnancy is an absolute contraindication for the use of lipid-lowering agents because the risks to the fetus outweigh
    P
    the short-term benefits of cholesterol reduction.

29.  o minimize Niaspan-associated flushing and headaches introduce with 500 mg QHS and titrate upwards every 4 weeks.
    T
    Take with a low-fat snack and aspirin (325 mg). The maximum nightly dose of Niaspan is 2000 mg. Niaspan is associated
    with a lower incidence of LFT elevation than previous sustained-release niacin products; however, LFTs still need periodic
    monitoring. The increase in HDL-C with Niaspan continues after 4 weeks. Transaminases should be checked after 6
    weeks of therapy then every 6-12 weeks for 6 months. Rechecking lipids may be deferred to 12 or even 16 weeks to
    see the maximum HDL-C effect, before titrating above 1000 mg QHS. Serum glucose and uric acid should be monitored
    periodically if patient is at risk for worsened glycemic control or gout.

30.  dvicor and Simcor are fixed combinations of extended-release niacin and lovastatin (Advicor) or simvastatin (Simcor).
    A
    These products may be useful for patients on a stable statin dose in whom niacin is going to be added, or for patients on a
    stable niacin dose for whom a statin dose for whom a statin is going to be added.

31.  he most common reasons for medication failure include: 1) the wrong medication, 2) the wrong dose, 3) failure to use
    T
    combination therapy, and 4) patient non-compliance. If the patient is compliant yet has failed to reach goal, referral to a
    specialty clinic is strongly recommended. Referral should also be considered for patients with familial dyslipidemia and
    patients
    requiring multiple risk factor management in a multidisciplinary setting.

32.  dvanced lipoprotein testing. In some patients with premature heart disease or Metabolic Syndrome, LDL-C and
    A
    non-HDL-C may underestimate the severity of the lipoprotein abnormality, leading to increased but unrecognized risk.
    It should not be used in patients who have LDL-C or non-HDL-C above target values. Advanced lipoprotein testing using
    the NMR Spectroscopy or measurement of apo B-100 can be considered in patients with:
    	    • strong family history of premature CHD
    	    • Metabolic Syndrome or type II diabetes mellitus
    	    • recurrent CHD events who are at lipid goal
    	    • patients with TG  150 but without other components of Metabolic Syndrome
    	    • combined lipid disorders which are difficult to treat to target
	        • an unexpected response to therapy




            2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults  18 Years Old - May 2008 – Page 8
Dyslipidemia Medications -
  See plan-specific formularies for coverage determinations

 Class                                   Medication                            Dosage Strengths
 Statins*                                atorvastatin (Lipitor)                10, 20, 40, 80 mg
 (Most HMOs include the statin class     fluvastatin (Lescol, XL)              20, 40, 80(XL) mg
 in their tablet splitting programs.)    lovastatin                            10, 20 40 mg
                                         lovastatin ER (Altoprev)              10, 20, 40, 60 mg SR
                                         pravastatin (Pravachol)               10, 20, 40, 80 mg
                                         rosuvastatin (Crestor)                5. 10, 20, 40 mg
                                         simvastatin (Zocor)                   5, 10, 20, 40, 80 mg
 Azetidione                              ezetimibe (Zetia)                     10 mg
 Nicotinic Acid                          Niaspan                               500, 750, 1000 mg
 Omega-3 fish oils                       Lovaza                                1 gram
                                         Super EPA 2000                        1000 mg
 Fibrates                                gemfibrozil                           600 mg
                                         fenofibrate                           67, 134, 200 mg
                                           (Tricor)                            45, 145 mg
                                           (Triglide)                          50, 160 mg
                                           (Antara)                            43, 87, 130 mg
                                           (Lipofen)                           50, 100, 150 mg
 Bile Acid sequestrants                  cholestyramine                        powder in packets or cans
                                         cholestyramine/light                  powder in packets or cans
                                         colesevelam (Welchol)                 625 mg tablets
                                         colestipol (Colestid)                 1G tabs, 5G granule packets
 Combinations                            ezetimibe/simvastatin (Vytorin)       10/10, 10/20, 10/40, 10/80 mg
                                         niacin/lovastatin (Advicor)           500/20, 1000/10 mg SR
                                         niacin extended release/simvastatin   500/20 mg, 750/20 mg, 1000/20 mg
                                         (Simcor)
                                         amlodipine/atorvastatin (Caduet)      2.5/10 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80
                                                                               10/10, 10/20, 10/40, 10/80 mg
                                         aspirin buffered/pravastatin          81/20, 81/40, 81/80, 325/20, 325/40, 325/80 mg
                                         (Pravigard PAC)


 Resources
Most medical groups have a provider experienced at treating patients with difficult to manage dyslipidemia. Please consult
regional facilities and providers for additional resources in your area. For specialty consultations or additional assistance,
contact the UW Hospital and Clinics Preventive Cardiology program.
University of Wisconsin Hospital and Clinics		 Phone	 608-263-1530				
Preventive Cardiology Program				                     608-263-7420
600 N. Highland Avenue				
Madison, WI 53792					
For additional nutrition information contact the UW Health Nutrition Center at 608-287-2780, or one of the UW Health
Outpatient Nutrition Clinics: UW Hospital 608-263-4360, West Clinic at 608-262-9181, East Clinic at 608-265-7405 or
University Station at 608-263-7772. Consult local facilities and providers for additional resources in your area.

National Cholesterol Education Program http://www.nhlbi.nih.gov/guidelines/cholesterol/
Useful patient and physician materials including on-line and downloadable risk calculators2 for desktop computers
and palm computers.
American Heart Association http://www.americanheart.org
Resources for patients and professionals.
American Dietetics Association http://www.eatright.org/nuresources.html
Resources for patients and professionals on healthy diets.


              2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults  18 Years Old - May 2008 – Page 9
References
•  rundy SM, et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment
  G
  Panel III Guidelines. Circulation 2004; 110: 227-239
•  xecutive Summary of the 3rd Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,
  E
  Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
• Grundy SM. Role of therapy with “statins” in patients with hypertriglyceridemia. Am J Cardiol 1998;81:1B-6B.
•  tone NJ, Blum CB, Winslow E. Management of lipids in clinical practice. 5th ed. Caddo, OK, Professional Communications,
  S
  Inc., 2005.
•  annon CP, et al.  Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes.  NEJM 2004;  
  C
  350: 1495-1504.
•  allantyne CM, et al.  Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin
  B
  in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study. American Heart Journal 2005;  149:
  464-473.
• McBride PE, Stein JH. Contemporary Diagnosis and management in Preventative Cardiology. Handbooks in Health Care, 	
  Newton, PA, 2006.


  Acknowledgements  Disclosures
University of Wisconsin Medical Foundation, University of Wisconsin Hospitals and Clinics, Meriter Hospital, Physicians Plus
Insurance Corporation, Unity Health Insurance and Group Health Cooperative have cooperated in the revision of these lipid
management guidelines.

James Stein, MD and Patrick McBride, MD, MPH, both from the UW Preventive Cardiology Program and the University of
Wisconsin School of Medicine and Public Health, led the revision efforts. Additional contributing task force members include:
Jessica Bartell, MD; Fred Brodsky, MD; Maggie Dugan, NP; Lawrence Fleming, MD, MBA; Derek Hubbard, MD; Pam Kittleson,
RPh; and Jennifer Schauer, PharmD.

Please direct questions, comments and suggestions regarding these guidelines to Pam Kittleson, RPh, UWMF provider
education pharmacist, at pamela.kittleson@uwmf.wisc.edu.

Reviewed and updated February 2008
Scheduled for reconsideration second quarter 2010

Disclosures
These faculty have disclosed the following:
  •   ames Stein, MD, Professor of Medicine, Division of Cardiovascular Medicine, and Director of the Preventive Cardiology
     J
     Program, University of Wisconsin School of Medicine and Public Health
     Scientific Consultant: Merck, Pfizer, Schering-Plough
     Research/training grants: Bristol-Myers Squibb, Kos, Sanofi-Aventis, Takeda
     Speaker's bureau: All honoraria donated directly to charity

  •   atrick McBride, MD, Professor of Medicine and Family Medicine, Division of Cardiovascular Medicine, University of
     P
     Wisconsin School of Medicine and Public Health
     Consultant: Johnson  Johnson, Reliant




          2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults  18 Years Old - May 2008 – Page 10

Mais conteúdo relacionado

Mais procurados

Indian lipid guideline 2016 dibu final
Indian lipid guideline 2016 dibu final Indian lipid guideline 2016 dibu final
Indian lipid guideline 2016 dibu final dibufolio
 
Dyslipidemia in stroke
Dyslipidemia in stroke  Dyslipidemia in stroke
Dyslipidemia in stroke NeurologyKota
 
Aace Guideline 2017: Management of Dyslipidemia and Prevention of Atheroscle...
Aace Guideline 2017:  Management of Dyslipidemia and Prevention of Atheroscle...Aace Guideline 2017:  Management of Dyslipidemia and Prevention of Atheroscle...
Aace Guideline 2017: Management of Dyslipidemia and Prevention of Atheroscle...Syed Mogni
 
Dyslpidemia Cme Com 25 May09
Dyslpidemia Cme  Com 25 May09Dyslpidemia Cme  Com 25 May09
Dyslpidemia Cme Com 25 May09Gauranga Dhar
 
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CAD
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CADTHE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CAD
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CADSunil Wadhwa
 
Diabetic dyslipidemia and residual risk by Dr. Vaibhav Yawalkar MD DM Cardiol...
Diabetic dyslipidemia and residual risk by Dr. Vaibhav Yawalkar MD DM Cardiol...Diabetic dyslipidemia and residual risk by Dr. Vaibhav Yawalkar MD DM Cardiol...
Diabetic dyslipidemia and residual risk by Dr. Vaibhav Yawalkar MD DM Cardiol...vaibhavyawalkar
 
Dyslipidemia 'from guidelines to practice' prof.alaa wafaa
Dyslipidemia 'from guidelines to practice' prof.alaa wafaaDyslipidemia 'from guidelines to practice' prof.alaa wafaa
Dyslipidemia 'from guidelines to practice' prof.alaa wafaaalaa wafa
 
Diabetic dyslipidemia and Saroglitazar
Diabetic dyslipidemia and SaroglitazarDiabetic dyslipidemia and Saroglitazar
Diabetic dyslipidemia and SaroglitazarDr Vivek Baliga
 
Ueda2016 new horizon in the management of dyslipidemia - diaa ewais
Ueda2016 new horizon in the management of dyslipidemia - diaa ewaisUeda2016 new horizon in the management of dyslipidemia - diaa ewais
Ueda2016 new horizon in the management of dyslipidemia - diaa ewaisueda2015
 

Mais procurados (20)

Low Hdl Hyper Tg
Low Hdl Hyper TgLow Hdl Hyper Tg
Low Hdl Hyper Tg
 
Hypertensive Dyslipidaemics
Hypertensive DyslipidaemicsHypertensive Dyslipidaemics
Hypertensive Dyslipidaemics
 
Indian lipid guideline 2016 dibu final
Indian lipid guideline 2016 dibu final Indian lipid guideline 2016 dibu final
Indian lipid guideline 2016 dibu final
 
Diabetic Dyslipidemia Slide Share
Diabetic  Dyslipidemia Slide ShareDiabetic  Dyslipidemia Slide Share
Diabetic Dyslipidemia Slide Share
 
Dyslipidemia in stroke
Dyslipidemia in stroke  Dyslipidemia in stroke
Dyslipidemia in stroke
 
Aace Guideline 2017: Management of Dyslipidemia and Prevention of Atheroscle...
Aace Guideline 2017:  Management of Dyslipidemia and Prevention of Atheroscle...Aace Guideline 2017:  Management of Dyslipidemia and Prevention of Atheroscle...
Aace Guideline 2017: Management of Dyslipidemia and Prevention of Atheroscle...
 
Dyslipidemia aha acc 2013
Dyslipidemia aha acc 2013Dyslipidemia aha acc 2013
Dyslipidemia aha acc 2013
 
Lipid guidelines
Lipid guidelinesLipid guidelines
Lipid guidelines
 
Dyslipidemia
DyslipidemiaDyslipidemia
Dyslipidemia
 
Dyslpidemia Cme Com 25 May09
Dyslpidemia Cme  Com 25 May09Dyslpidemia Cme  Com 25 May09
Dyslpidemia Cme Com 25 May09
 
Dyslipidemia
DyslipidemiaDyslipidemia
Dyslipidemia
 
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CAD
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CADTHE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CAD
THE ROLLER COASTER RIDE OF DYSLIPIDEMIA & CAD
 
Dyslipidaemia
DyslipidaemiaDyslipidaemia
Dyslipidaemia
 
Dyslipidemia Guidelines 2016
Dyslipidemia Guidelines 2016Dyslipidemia Guidelines 2016
Dyslipidemia Guidelines 2016
 
Diabetic dyslipidemia
Diabetic dyslipidemiaDiabetic dyslipidemia
Diabetic dyslipidemia
 
Diabetic dyslipidemia and residual risk by Dr. Vaibhav Yawalkar MD DM Cardiol...
Diabetic dyslipidemia and residual risk by Dr. Vaibhav Yawalkar MD DM Cardiol...Diabetic dyslipidemia and residual risk by Dr. Vaibhav Yawalkar MD DM Cardiol...
Diabetic dyslipidemia and residual risk by Dr. Vaibhav Yawalkar MD DM Cardiol...
 
Dyslipidemia 'from guidelines to practice' prof.alaa wafaa
Dyslipidemia 'from guidelines to practice' prof.alaa wafaaDyslipidemia 'from guidelines to practice' prof.alaa wafaa
Dyslipidemia 'from guidelines to practice' prof.alaa wafaa
 
Diabetic dyslipidemia and Saroglitazar
Diabetic dyslipidemia and SaroglitazarDiabetic dyslipidemia and Saroglitazar
Diabetic dyslipidemia and Saroglitazar
 
Ueda2016 new horizon in the management of dyslipidemia - diaa ewais
Ueda2016 new horizon in the management of dyslipidemia - diaa ewaisUeda2016 new horizon in the management of dyslipidemia - diaa ewais
Ueda2016 new horizon in the management of dyslipidemia - diaa ewais
 
dyslipidemia
dyslipidemiadyslipidemia
dyslipidemia
 

Destaque (20)

Dnr mediakit rus
Dnr mediakit rusDnr mediakit rus
Dnr mediakit rus
 
demoday presentation ny
demoday presentation nydemoday presentation ny
demoday presentation ny
 
Doctors networks analysis
Doctors networks analysisDoctors networks analysis
Doctors networks analysis
 
Happy valentines day
Happy valentines dayHappy valentines day
Happy valentines day
 
Sample MoveNinja screens
Sample MoveNinja screensSample MoveNinja screens
Sample MoveNinja screens
 
Dnr mediakit
Dnr mediakitDnr mediakit
Dnr mediakit
 
Dnr mediakit
Dnr mediakitDnr mediakit
Dnr mediakit
 
Dnr mediakit
Dnr mediakitDnr mediakit
Dnr mediakit
 
D6930520 7b49-414f-b769-f12b0a9ac90c
D6930520 7b49-414f-b769-f12b0a9ac90cD6930520 7b49-414f-b769-f12b0a9ac90c
D6930520 7b49-414f-b769-f12b0a9ac90c
 
Physicians Internet Monitoring
Physicians Internet MonitoringPhysicians Internet Monitoring
Physicians Internet Monitoring
 
DocInternet Monitoring
DocInternet MonitoringDocInternet Monitoring
DocInternet Monitoring
 
Attitude modificationvnr
Attitude modificationvnrAttitude modificationvnr
Attitude modificationvnr
 
DemoDay presentation
DemoDay presentationDemoDay presentation
DemoDay presentation
 
Dnr mediakit
Dnr mediakitDnr mediakit
Dnr mediakit
 
DoctorAtWork Mediakit
DoctorAtWork MediakitDoctorAtWork Mediakit
DoctorAtWork Mediakit
 
Approved Resume
Approved ResumeApproved Resume
Approved Resume
 
Dnr mediakit
Dnr mediakitDnr mediakit
Dnr mediakit
 
Dnr mediakit
Dnr mediakitDnr mediakit
Dnr mediakit
 
Dnr mediakit
Dnr mediakitDnr mediakit
Dnr mediakit
 
Retention and success
Retention and successRetention and success
Retention and success
 

Semelhante a Dyslipidemia protocol

Dyslipidaemia part one.pdf
Dyslipidaemia part one.pdfDyslipidaemia part one.pdf
Dyslipidaemia part one.pdfssuser0ec0d3
 
Diabetic dyslipidemia
Diabetic dyslipidemiaDiabetic dyslipidemia
Diabetic dyslipidemiaFarragBahbah
 
Primary prevention stroke
Primary prevention strokePrimary prevention stroke
Primary prevention strokeNeurologyKota
 
Dyslipidemia presentation.pptx
Dyslipidemia presentation.pptxDyslipidemia presentation.pptx
Dyslipidemia presentation.pptxMuhammadAdil39044
 
Lec 6 preventive cardiology for mohs
Lec 6  preventive cardiology for mohsLec 6  preventive cardiology for mohs
Lec 6 preventive cardiology for mohsEhealthMoHS
 
ATP IV Guideline for Blood cholesterol level
ATP IV Guideline for Blood cholesterol levelATP IV Guideline for Blood cholesterol level
ATP IV Guideline for Blood cholesterol levelkamalmodi481
 
Prevention guidelines cholesterol
Prevention guidelines   cholesterolPrevention guidelines   cholesterol
Prevention guidelines cholesterolMohammad Alzanfaly
 
Ueda2015 d.dyslipidemia dr.khaled hadidy
Ueda2015 d.dyslipidemia dr.khaled hadidyUeda2015 d.dyslipidemia dr.khaled hadidy
Ueda2015 d.dyslipidemia dr.khaled hadidyueda2015
 
RIESGO CARDIOMETABOLICO
RIESGO CARDIOMETABOLICORIESGO CARDIOMETABOLICO
RIESGO CARDIOMETABOLICODaniel Meneses
 
Slides-Cholesterol.ppt
Slides-Cholesterol.pptSlides-Cholesterol.ppt
Slides-Cholesterol.pptLawer Emmanuel
 
serum-lipid-abnormalities(1)
serum-lipid-abnormalities(1)serum-lipid-abnormalities(1)
serum-lipid-abnormalities(1)Khurram Iqbal
 
Cardio updates 2019 power point template
Cardio updates 2019 power point templateCardio updates 2019 power point template
Cardio updates 2019 power point templateHaytham Ghareeb
 
ESC guideline for CVD prevention 2021..pptx
ESC guideline for CVD prevention 2021..pptxESC guideline for CVD prevention 2021..pptx
ESC guideline for CVD prevention 2021..pptxAshfakAlArifShuvon
 
Diabetes and Cardiovascular Disease
Diabetes and Cardiovascular DiseaseDiabetes and Cardiovascular Disease
Diabetes and Cardiovascular Diseasescsinha
 
Peer to peer Case Discussion - ASCVD^.pptx
Peer to peer Case Discussion - ASCVD^.pptxPeer to peer Case Discussion - ASCVD^.pptx
Peer to peer Case Discussion - ASCVD^.pptxMohammed Dhamin Alareedh
 

Semelhante a Dyslipidemia protocol (20)

Dyslipidemia Guidlines
Dyslipidemia GuidlinesDyslipidemia Guidlines
Dyslipidemia Guidlines
 
Dyslipidaemia part one.pdf
Dyslipidaemia part one.pdfDyslipidaemia part one.pdf
Dyslipidaemia part one.pdf
 
Dyslipdemia Guidelines Head to Head
Dyslipdemia Guidelines Head to HeadDyslipdemia Guidelines Head to Head
Dyslipdemia Guidelines Head to Head
 
Diabetic dyslipidemia
Diabetic dyslipidemiaDiabetic dyslipidemia
Diabetic dyslipidemia
 
Dyslypedia
DyslypediaDyslypedia
Dyslypedia
 
lipid guidelines.pptx
lipid guidelines.pptxlipid guidelines.pptx
lipid guidelines.pptx
 
Primary prevention stroke
Primary prevention strokePrimary prevention stroke
Primary prevention stroke
 
Dyslipidaemia highlights
Dyslipidaemia highlights Dyslipidaemia highlights
Dyslipidaemia highlights
 
Dyslipidemia presentation.pptx
Dyslipidemia presentation.pptxDyslipidemia presentation.pptx
Dyslipidemia presentation.pptx
 
Lec 6 preventive cardiology for mohs
Lec 6  preventive cardiology for mohsLec 6  preventive cardiology for mohs
Lec 6 preventive cardiology for mohs
 
ATP IV Guideline for Blood cholesterol level
ATP IV Guideline for Blood cholesterol levelATP IV Guideline for Blood cholesterol level
ATP IV Guideline for Blood cholesterol level
 
Prevention guidelines cholesterol
Prevention guidelines   cholesterolPrevention guidelines   cholesterol
Prevention guidelines cholesterol
 
Ueda2015 d.dyslipidemia dr.khaled hadidy
Ueda2015 d.dyslipidemia dr.khaled hadidyUeda2015 d.dyslipidemia dr.khaled hadidy
Ueda2015 d.dyslipidemia dr.khaled hadidy
 
RIESGO CARDIOMETABOLICO
RIESGO CARDIOMETABOLICORIESGO CARDIOMETABOLICO
RIESGO CARDIOMETABOLICO
 
Slides-Cholesterol.ppt
Slides-Cholesterol.pptSlides-Cholesterol.ppt
Slides-Cholesterol.ppt
 
serum-lipid-abnormalities(1)
serum-lipid-abnormalities(1)serum-lipid-abnormalities(1)
serum-lipid-abnormalities(1)
 
Cardio updates 2019 power point template
Cardio updates 2019 power point templateCardio updates 2019 power point template
Cardio updates 2019 power point template
 
ESC guideline for CVD prevention 2021..pptx
ESC guideline for CVD prevention 2021..pptxESC guideline for CVD prevention 2021..pptx
ESC guideline for CVD prevention 2021..pptx
 
Diabetes and Cardiovascular Disease
Diabetes and Cardiovascular DiseaseDiabetes and Cardiovascular Disease
Diabetes and Cardiovascular Disease
 
Peer to peer Case Discussion - ASCVD^.pptx
Peer to peer Case Discussion - ASCVD^.pptxPeer to peer Case Discussion - ASCVD^.pptx
Peer to peer Case Discussion - ASCVD^.pptx
 

Último

Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 

Último (20)

Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 

Dyslipidemia protocol

  • 1. Diagnosis and Management of Dyslipidemia for Adults 18 Years of Age The Clinical Practice Guidelines for the Diagnosis and Management of Dyslipidemia for Adults 18 Years of Age was reviewed and approved by Unity’s Clinical Quality Improvement Committee (CQIC) on May 16, 2008. The guideline was previously approved by CQIC on November 18, 2005, September 17, 2004, September 11, 2003, September 10, 2001, March 5, 2001, and June 29, 1999. The UW Medical Foundation, UW Hospitals and Clinics, Meriter Hospital, Unity Health Insurance, Physicians Plus Insurance Corporation, and Group Health Cooperative participated in the development and revision of this guideline. The task force was a multidisciplinary work group comprised of physicians, pharmacists, a nurse practitioner and a nutritionist.
  • 2. 2008 GUIDELINE FOR THE DIAGNOSIS AND MANAGEMENT OF DYSLIPIDEMIA FOR ADULTS > 18 YEARS OF AGE This clinical guideline is designed to assist clinicians by providing a framework for the evaluation and treatment of patients with or at risk for dyslipidemia. It is not intended to replace a clinician's judgement or to establish a protocol for the treatment of a particular condition. A guideline rarely will establish the only approach to a problem. CONTENTS 1. Treatment Overview of Dyslipidemia...................................................................................................................................2 2. Major CHD Risk Factors (Exclusive of LDL-C) ....................................................................................................................2 3. Screening Guidelines ..........................................................................................................................................................3 4. Lipid Treatment Goals and Cutpoints ..................................................................................................................................3 5. General Treatment Sequence Recommendations................................................................................................................4 6. Medication-Specific Treatment Recommendations .............................................................................................................6 7. Dose Equivalence Approximations ......................................................................................................................................7 8. Profiles of Major Medication Classes..................................................................................................................................7 9. Follow-up Evaluation and Maintenance Therapy .................................................................................................................8 10. Dyslipidemia Medications .................................................................................................................................................9 11. Resources .........................................................................................................................................................................9 12. References ......................................................................................................................................................................10 13. Acknowledgements & Disclosures .................................................................................................................................10 2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults ≥ 18 Years Old - May 2008 - Page 1 UM13973-1107P
  • 3. Treatment Overview of Dyslipidemia Dyslipidemia is a powerful risk factor for coronary heart disease (CHD). Clinical trials conclusively have demonstrated that treatment of lipid disorders can reduce CHD morbidity and mortality. Treatment of lipid disorders also helps prevent stroke and peripheral arterial disease. 1. asic principle. The intensity of risk-reduction therapy should be based on the patient’s risk of a CHD event. B Patients with established CHD have a 10-year risk of having a CHD event (cardiac death or myocardial infarction) that is 20% ( 2%/year). Accordingly, primary prevention patients with a similar risk (“CHD Risk Equivalent”) should be treated as aggressively. Such patients include those with non-coronary atherosclerosis (cerebrovascular disease, peripheral vas- cular disease, abdominal aortic aneurysm), type 2 diabetes mellitus, or an estimated 10-year CHD risk 20% using the Framingham risk factor equation. Similarly, the CHD risk of patients with extreme lipid abnormalities such as low-density lipoprotein cholesterol (LDL-C) 190, high-density lipoprotein cholesterol (HDL-C) 40, or triglycerides (TG) 500 mg/ dL) qualify for aggressive treatment. These patients often have genetic disorders and their CHD risk is not reflected ade- quately by standard risk prediction techniques. 2. ethods of risk assessment. Risk assessment is accomplished by a 2-step procedure. Count the number of major risk M factors3 (not including LDL-C). For persons with 2 or more risk factors, refine risk assessment using the Framingham risk factor equation. Easy to use, computerized and chart-based scoring tools to estimate 10-year risks of CHD events are available online at http://www.nhlbi.nih.gov/guidelines/cholesterol and at http://hin.nhlbi.nih.gov/atpiii/calculator. asp?usertype=prof. For screening and treatment, individuals can be categorized into five general risk categories: 1. Very High – Recent acute coronary syndrome19 • • CHD or non-coronary atherosclerotic vascular disease1 and one of the following: - Diabetes mellitus - Metabolic Syndrome8 - Current smoking - Chronic kidney disease 2. igh – CHD or CHD risk equivalent. Patients with extensive subclinical atherosclerosis, chronic kidney disease H and recipients of solid organ transplant are also at high risk. 3. Moderately High – No CHD with 2 risk factors and 10 yr CHD risk 10-20% 4. Moderate –No CHD with 2 risk factors and 10 yr CHD risk 10% 5. Lower – No CHD with 1 risk factor Major CHD Risk Factors (Exclusive of LDL-C) 3. n addition to high LDL-C, several factors increase the risk of CHD. I • Current cigarette smoking • Hypertension (blood pressure 140/90 mmHg or current treatment with antihypertensive medication) • Low HDL-C ( 40 mg/dL) • Family history of premature CHD (1st-degree relative: male 55 or female 65 years old) • Age (male 45, female 55 years old) Note: HDL-C 60 mg/dL can be considered a negative risk factor. Its presence may remove one risk factor from the count. 2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults 18 Years Old - May 2008 – Page 2
  • 4. Screening Guidelines Screening Risk Group Begin Screening Frequency Test CHD, CHD risk equivalent, or 2 risk factors Age 20 years or at onset Yearly Fasting lipid panel Familial dyslipidemia or family history of premature CHD Age 20 years 2 years Fasting lipid panel None of the above Age 20 years 5 years Fasting lipid panel or non-fasting total cholesterol and HDL-C4 4. creening to determine the presence of atherosclerosis or risk factors can occur at any routine visit. If non-fasting S lipids are measured, obtain a fasting lipid profile if total cholesterol is 200 mg/dL or HDL-C is 40 mg/dL in a male or 50 mg/dL in a female. 5. or rare patients with CHD or a CHD risk equivalent but no evidence of a dyslipidemia, re-screen every year F depending on presence of associated risk factors. L ipid Treatment Goals and Cutpoints Revised ATP III LDL-C goals based on recent clinical trial evidence Treatment Risk Group Primary Target = LDL-C Consider Medication Secondary Target= Non- Therapy* HDL-C7(if TG 200) Very High2 LDL-C 70 70 100 High–CHD or CHD risk LDL-C 100 ( 70 optional6) 100 Non-HDL-C 130 equivalent Moderately High–No CHD LDL-C 130 130 Non-HDL-C 160 with 2 risk factors and 10 yr CHD risk 10-20% Moderate–No CHD with 2 LDL-C 130 160 Non-HDL-C 160 risk factors and 10 yr CHD risk 10% Lower–No CHD with 1 risk LDL-C 160 190 Non-HDL-C 190 factor *Based on health care providers judgement, it is optional to treat patients to the lipid targets at the next higher level of RISK. For example, an LDL-C target of 70mg/dL is optional in all patients with CHD (see below). An LDL-C of 100 mg/dl is an option in patients at moderately high risk. 6. ptional target LDL-C 70 mg/dL. Option for anyone with CHD, but recommended for the following groups of CHD O patients: • Baseline LDL-C 100 mg/dL at time of diagnosis • Acute coronary syndrome • Diabetes mellitus • Severe, poorly controlled risk factors, especially smoking • ultiple risk factors of Metabolic Syndrome8, especially TG 200 and HDL-C 40 mg/dL M • Chronic kidney disease 7. on-HDL-C = total cholesterol minus HDL-C. When triglycerides are 200 mg/dL, LDL-C levels are measured less N accurately and may underestimate CHD risk. Therefore, for patients with elevated TG levels, treatment of the non-HDL-C level is a secondary target after the LDL-C target has been reached. The non-HDL-C level includes cholesterol carried in several atherogenic lipoproteins, such as LDL, very low-density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and lipoprotein (a). 2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults 18 Years Old - May 2008 – Page 3
  • 5. 8. etabolic Syndrome. This is a common condition associated with increased CHD risk. Metabolic abnormalities include: M hyperinsulinemia often accompanied by glucose intolerance, abdominal obesity, hypertension, hyperuricemia, prothrombot- ic state, proinflammatory state, and the atherogenic lipoprotein phenotype (low HDL-C, hypertriglyceridemia, small dense LDL particles). Treatment of insulin resistance with exercise, weight loss and medications is a secondary target of therapy, in addition to lipid goals. The diagnosis of metabolic syndrome depends on the presence of three (3) or more of the follow- ing factors: • waist 40 for males, 35 for females (lower for Asian Americans: 35 for males, 31 for females; and for patients with genetic disposition: 37 in males and 31 in females) • fasting glucose 100 mg/dL • TG 150 mg/dL • HDL-C 40 mg/dL males, 50 mg/dL females • lood pressure 130/85 mmHg or current treatment with antihypertensive medication b 9 T . ype 2 diabetes mellitus and non-coronary atherosclerosis are CHD risk equivalents. Optimization of glycemic control may reduce TG. Use of metformin and pioglitazone may simplify the management of diabetic dyslipidemia because they raise HDL-C, lower TG levels, and reduce the number of small LDL particles. 10. Secondary causes of hyperlipidemia should be identified and treated: • type 2 diabetes mellitus9 • Metabolic Syndrome8 • hypothyroidism • obstructive liver disease • renal disease • corticosteroid use • progestin use • anabolic steroid use • alcohol use 11. herapeutic Lifestyle Changes (TLC). These should be instituted in all patients if LDL-C or non HDL-C are above goal. T The TLC diet involves reduced intake of cholesterol-raising nutrients such as saturated and trans-fats, which should be restricted to 7% of calories. Dietary cholesterol is restricted to 200 mg per day. Additional LDL-C lowering options include 2 grams of plant stanol or sterols per day (fortified margines, yogurts, juices, etc.) and soluble fiber (3–6 g daily). Additional TG-lowering options include use of fish oil (omega-3 fatty acid) supplements (3-6 g daily). Weight reduction and increased physical activity are critical for the management of all dyslipidemias and to improve cardiovascular fitness. More information on TLC can be found within the NHBLI website at: http://rover2.nhlbi.nih.gov/chd/lifestyles.htm. General Treatment Sequence Recommendations Medication Sequence Lipid Pattern TG 200 mg/dL TG 200 – 499 mg/dL TG 500 mg/dL 1st statin13 statin13 or niacin14 niacin14, fish oils or fibrate 2nd add niacin14, BAS17, or ezetimibe16 statin + niacin14 combination of niacin14, fish oils or fibrate 3rd add niacin14, BAS17, or ezetimibe16 add ezetimibe16 add third TG-lowering medication, consider a statin 12. eneral Principles of medication therapy. Medication therapy should be started if LDL-C or non-HDL-C are above target G values. For patients with CHD or CHD risk equivalent, medication therapy may be considered in combination with TLC at any time. Patients at high risk and very high risk should start medication therapy immediately. The decision to initiate medication treatment usually commits patients to lifelong therapy. In general, single medication therapy is initiated; however, the lipid- lowering effect is not directly proportional to the dose. A 30-40% LDL-C reduction should be targeted. Doubling a statin dose may decrease LDL-C by an additional 5% to 7%. Doses reaching or exceeding maximum daily doses have little or no benefit and increase the risk of side-effects. Combination therapy frequently will increase the likelihood of reaching lipid goals. TLC should be instituted prior to or concurrent with medication therapy. All patients with dyslipidemia should be referred for dietary counseling, preferably with a trained provider. 13. he TG-lowering effects of statins are dose- and potency-dependent. As TG levels increase, higher doses of statins are T required. For moderate elevations of LDL-C in patients with elevated TG, prescription niacin (Niaspan)14 is an alternative. In general, statins should not be used alone in patients with TG 500 mg/dL. 2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults 18 Years Old - May 2008 – Page 4
  • 6. 14. he American Heart Association recommends use of a prescription niacin (Niaspan) rather than niacin supplements. T Supplements are not regulated and often contain more or less than the labeled amount of niacin, vary from lot to lot, and some are more hepatotoxic. 15. n general, the combination of statins and fibrates is discouraged. If this combination must be used, fenofibrate is safer I than gemfibrozil. If gemfibrozil is used, statin doses should be kept low. Be very cautious in older patients, those with kidney disease, and those on medications that affect statin metabolism. 16. zetimibe inhibits intestinal cholesterol absorption. Statins are considered first line therapy for patients requiring E LDL-C reduction. Use ezetimibe in combination with statins for those patients unable to reach goal on highest tolerated dose of a statin. BAS and niacin also may be used. Ezetimibe reduces LDL-C by 17-23%. Ezetimibe is a first line agent only for patients with contraindications or medication intolerances to statins. This medicine has not been proven to reduce CHD events. 17. ile acid sequestrants (BAS) can raise TG levels. If TG levels are elevated at follow-up, consider switching to Niaspan14. B 18. mega-3 polyunsaturated fats (fish oils) at doses of 3-6 g/day lower TG levels by 30-50%. They should be administered O with meals. Prescription fish oil (Lovaza) is available. Most fish oil preparations that are available as dietary supplements are effective and also appear to be free of contaminants, but tend to be less potent. A non-prescription alternative that can be used is SUPER-EPA 2000. Fish oils are safe when used in combination with other lipid-lowering medications. 19. cute MI patients. LDL-C and HDL-C levels may be artificially low due to inflammation during acute illnesses, such as A acute coronary or cerebral syndromes. Heparin also can decrease TG levels. If lipid levels are checked in hosptialized patients it should be recognized that they tend to underestimate ambulatory, usual lipid levels. For patients with acute syn- dromes, high-dose statin therapy (e.g., atorvastatin 80 mg/dL) should be initiated to target LDL-C (70 mg/dL). Rapid and aggressive reduction of LDL-C after an acute coronary syndrome improves clinical outcomes. 20. ollowing LDL-C after an Acute Cardiac Event. For patients with an inpatient hospital stay for an acute cardiac event, F LDL-C should be checked at least one time between 42 and 365 days after discharge to assure the patient is at target. 21. ow HDL-C. Low HDL-C is very common in persons with premature CHD, particularly males 45 and females 55 L years old. A goal is to raise HDL-C as much as possible, by treating associated causes (hypertriglyceridemia, Metabolic Syndrome, physical inactivity, cigarette smoking, excessively high carbohydrate diets, etc). Achieving LDL-C and non- HDL-C targets and treatment of the Metabolic Syndrome are the dominant strategies. An isocaloric increase in dietary monounsaturated fats may help. For patients with isolated low HDL-C in whom medication therapy is appropriate, consider Niaspan 1000-2000 mg QHS, fish oils or fibrates in patients with elevated TG. Additional LDL-C lowering with a statin may be considered. 22. en 35 years old and pre-menopausal women. The 10-year risk of CHD events is low unless they have severe risk M factors, such as familial hypercholesterolemia, cigarette smoking, or diabetes mellitus. Even though clinical CHD is uncom- mon, subclinical atherosclerosis can progress rapidly. Furthermore, CHD is a lifelong disease and risk factors in youth pre- dict premature CHD. TLC is the dominant strategy for young patients; however, medication therapy should be considered. Patients with extreme lipid abnormalities also should be treated aggressively. 2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults 18 Years Old - May 2008 – Page 5
  • 7. 23. Medication-Specific Treatment Recommendations* Very High2 TG Level RX Goal Start and maximize Then add or switch to 499 LDL-C 70 atorvastatin 40-80 mg, simvastatin 40-80 mg or Add Niaspan 1000-2000 mg daily or BAS Vytorin 20-80/10 mg** 500 LDL-C 70 and Niaspan 2000 mg, omega-3 fish oils 4 g or Add Niaspan, omega-3 fish oils, fenofibrate, non-HDL-C 100 fenofibrate 200 mg or statin High – CHD OR CHD Equivalent TG 200 LDL-C 100 (optional If LDL-C 100, simvastatin 20-40 mg or lovas- If patients don’t tolerate or reach goal on a 706) tatin 40 mg QHS. If LDL-C 130, simvastatin high dose statin alone, add Niaspan 1000 40 mg mg-2000 mg QHS, ezetimibe, or BAS. TG 200-499 LDL-C 100 and Non- simvastatin 20-40 mg QHS Add Niaspan 1000-2000 mg QHS HDL-C 130 TG 500 LDL-C 100 and Non- Niaspan 2000 mg QHS, omega-3 fish oils, or Add Niaspan or omega-3 fish oils or fibrate HDL-C 130 gemfibrozil 600 mg BID or fenofibrate 200 mg QD Moderately High/Moderate – Primary Prevention 2 Risk Factors and 10-year CHD Risk 20% TG 200 LDL-C 130 If LDL-C 130, simvastatin 20 mg or lovastatin If patients don’t tolerate or reach goal on a 40 mg QHS high dose statin alone, add Niaspan 1000 If LDL-C 160, simvastatin 20 – 40 mg or lovas- mg-2000 mg QHS, ezetimibe, or BAS. tatin 40-80 mg QHS If LDL-C 190, simvastatin 40 mg QHS TG 200-499 LDL-C 130 and Non- simvastatin 20-40 mg Add Niaspan 1000-2000 mg QHS HDL-C 160 TG 500 LDL-C 130 and Non- Niaspan 2000 mg QHS or omega-3 fish oils, Add Niaspan or omega-3 fish oils or fibrate HDL-C 160 gemfibrozil 600 mg BID or fenofibrate 200 mg QD Low – Primary Prevention 1 Risk Factor TG 200 LDL-C 160 If LDL-C 160, simvastatin 20 mg or lovastatin If patients don’t tolerate or reach goal on a 40 mg QHS high dose statin alone, add Niaspan 1000 If LDL-C 190 simvastatin 20-40 mg or lovasta- mg-2000 mg QHS, ezetimibe, or BAS. tin 40-80 mg QHS If LDL-C 220, simvastatin 40 mg QHS TG 200-499 LDL-C 160 and Non- simvastatin 20-40 mg or lovastatin 40-80 mg Add Niaspan 1000-2000 mg QHS HDL-C 190 QHS TG 500 LDL-C 160 and Non- Niaspan 2000 mg QHS, omega-3 fish oils or Add Niaspan, omega-3 fish oils or fibrate HDL-C 190 gemfibrozil 600 mg BID or fenofibrate 200 mg QD * pecific treatment recommendations were made based on local HMO formulary coverages. These are subject to change at any time. S If switching to an alternative statin, use Table 24, below, for approximate equipotent dosing. **This combination increases the chances of getting LDL-C to goal, but has not been proven to reduce cardiac events. Consider referral to UW Health Preventative Cardiology Clinic for complicated patients with refractory dyslipidemia (requiring more than 2 medications to reach target), suspected genetic dyslipidemias, medication intolerances or patients with secondary causes. 2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults 18 Years Old - May 2008 – Page 6
  • 8. 24. Dose Equivalence Approximations (for available strengths) atorvastatin fluvastatin lovastatin pravastatin simvastatin rosuvastatin simvastatin/ ezetimibe ---- 20 mg 10 mg 10 mg 5 mg ---- ---- Approximate 5 mg 40 mg 20 mg 20 mg 10 mg ---- ---- Equipotent 10 mg 80 mg 40 mg 40 mg 20 mg 5 mg ---- Dose 20 mg ---- 80 mg 80 mg 40 mg 10 mg 10 mg/10 mg 40 mg ---- ---- ---- 80 mg 20 mg 10 mg/20 mg 80 mg ---- ---- ---- ---- 40 mg 10 mg/40 mg ---- ---- ---- ---- ---- ---- 10 mg/80 mg If changing statins, start on equivalent dose and recheck LDL-C levels and transaminases after 6-8 weeks. Simvastatin, lovastatin, and atorvastatin are metabolized by the CYP3A4 system, a common metabolic pathway for many medications includ- ing, but not limited to, protease inhibitors, azole antifungals, macrolide antibiotics and cyclosporine. Consider using other statins in patients with renal insufficiency or patients on multiple medications with other medications metabolized by this isoenzyme system (such as verapamil, diltiazem, or amiodarone). 25. Profiles of Major Medication Classes Statins Azetidinone Nicotinic Acid Omega-3 Fibrates Bile Acid Fish Oils Sequestrants Medications atorvastatin (Lipitor) ezetimibe (Zetia)16 prescription niacin Lovaza gemfibrozil cholestyramine fluvastatin (Niaspan)14 fenofibrate cholestyramine light lovastatin extended-release (Lofibra, Tricor, colesevelam pravastatin niacin/lovastatin Antara) (Welchol) rosuvastatin*(Crestor) (Advicor)30 simvastatin extended release niacin/simvastatin (Simcor)30 Lipid Effects LDL-C lower 18-60% lower 17-23% lower 10-25% may raise lower 5-20% lower 15-30% (may raise) HDL-C raise 5-15% raise 2% raise 15-35% raise raise 10-20% raise 3-5% TG lower 7-30% lower 4-11% lower 20-50% lower 30-50% lower 20-50% none or raise Major Use elevated LDL-C, mild to elevated LDL -C moderately elevated TG ≥ 500 mg/dl TG 400 mg/dL moderately elevated moderately LDL-C, elevated TG, LDL-C with normal elevated TG, mildly low low HDL-C TG HDL-C Contraindication liver disease, severe liver disease liver disease, none pregnancy28 bowel obstruction - Absolute pregnancy28 pregnancy28 - Relative concomitant use gout, hyperuricemia liver or severe TG 200 mg/dL of fibric acid renal disease, gall- derivatives27 stones Long Term Safety extensive clinical use, 3 years safety data for 10 years yes yes 10-yr safety data Niaspan Major Side Effects myopathy, myalgia, well tolerated by flushing29, flatulence dyspepsia, gall- constipation, abdominal pain, hepa- most abdominal pain, gout, indigestion stone pain, hepato- flatulence, totoxicity hyperglycemia, hepato- burping toxicity decreased medica- toxicity, ulcers tion absorption Usual Daily Dose see medication-specific 10 mg QD Niaspan29 1000-2000 4g QD G¶ = 600 mg BID cholestyramine treatment table23 mg QHS L = 67-200 mg QD 4-16 g daily Advicor 500/20 mg- T = 54-160 mg QD colesevelam 2000/40 mg 3750 mg daily Simcor 1000/20 mg- 2000/40 mg Maximum Daily see medication-specific 10 mg QD Niaspan 1000-2000 mg 4g QD G= 600 mg BID cholestyramine Dose treatment table23 QHS L = 200 mg QD 24 g daily Advicor 2000/40 mg T = 160 mg QD colesevelam Simcor 2000/40 mg 4375 mg daily LFT Monitoring27 0,2 then q 12 mos. 0,2, then q 12 mos 0,2,6 then q 12 mos. none 0,2,6 then q 12 mos. none CPK monitoring27 muscle aches, pains, none muscle aches, pains, none muscle aches, pains, none tenderness tenderness tenderness ¶G=gemfibrozil, L=Lofibra, T=Tricor 2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults 18 Years Old - May 2008 – Page 7
  • 9. Follow up Evaluation and Maintenance Therapy 26. asting lipid levels should be obtained 6-8 weeks following the initiation or alteration of therapy. For patients at goal, lipid F profiles should be performed annually. 27. atients should be monitored for side effects of antilipidemic therapy as outlined in the medication profiles above. All P medications can cause transaminase elevation (incidence approximately 1%) and myopathy ( 0.1%). The risk is higher at the higher statin doses. If ALT or AST 3x normal or if the patient develops myopathy with an elevated CPK-MM fraction, the antilipidemic agent dose should be reduced, the agent should be changed, or the patient referred for further evaluation by a lipid management specialist. Transaminase should be repeated to assess progression or resolution. 28. regnancy is an absolute contraindication for the use of lipid-lowering agents because the risks to the fetus outweigh P the short-term benefits of cholesterol reduction. 29. o minimize Niaspan-associated flushing and headaches introduce with 500 mg QHS and titrate upwards every 4 weeks. T Take with a low-fat snack and aspirin (325 mg). The maximum nightly dose of Niaspan is 2000 mg. Niaspan is associated with a lower incidence of LFT elevation than previous sustained-release niacin products; however, LFTs still need periodic monitoring. The increase in HDL-C with Niaspan continues after 4 weeks. Transaminases should be checked after 6 weeks of therapy then every 6-12 weeks for 6 months. Rechecking lipids may be deferred to 12 or even 16 weeks to see the maximum HDL-C effect, before titrating above 1000 mg QHS. Serum glucose and uric acid should be monitored periodically if patient is at risk for worsened glycemic control or gout. 30. dvicor and Simcor are fixed combinations of extended-release niacin and lovastatin (Advicor) or simvastatin (Simcor). A These products may be useful for patients on a stable statin dose in whom niacin is going to be added, or for patients on a stable niacin dose for whom a statin dose for whom a statin is going to be added. 31. he most common reasons for medication failure include: 1) the wrong medication, 2) the wrong dose, 3) failure to use T combination therapy, and 4) patient non-compliance. If the patient is compliant yet has failed to reach goal, referral to a specialty clinic is strongly recommended. Referral should also be considered for patients with familial dyslipidemia and patients requiring multiple risk factor management in a multidisciplinary setting. 32. dvanced lipoprotein testing. In some patients with premature heart disease or Metabolic Syndrome, LDL-C and A non-HDL-C may underestimate the severity of the lipoprotein abnormality, leading to increased but unrecognized risk. It should not be used in patients who have LDL-C or non-HDL-C above target values. Advanced lipoprotein testing using the NMR Spectroscopy or measurement of apo B-100 can be considered in patients with: • strong family history of premature CHD • Metabolic Syndrome or type II diabetes mellitus • recurrent CHD events who are at lipid goal • patients with TG 150 but without other components of Metabolic Syndrome • combined lipid disorders which are difficult to treat to target • an unexpected response to therapy 2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults 18 Years Old - May 2008 – Page 8
  • 10. Dyslipidemia Medications - See plan-specific formularies for coverage determinations Class Medication Dosage Strengths Statins* atorvastatin (Lipitor) 10, 20, 40, 80 mg (Most HMOs include the statin class fluvastatin (Lescol, XL) 20, 40, 80(XL) mg in their tablet splitting programs.) lovastatin 10, 20 40 mg lovastatin ER (Altoprev) 10, 20, 40, 60 mg SR pravastatin (Pravachol) 10, 20, 40, 80 mg rosuvastatin (Crestor) 5. 10, 20, 40 mg simvastatin (Zocor) 5, 10, 20, 40, 80 mg Azetidione ezetimibe (Zetia) 10 mg Nicotinic Acid Niaspan 500, 750, 1000 mg Omega-3 fish oils Lovaza 1 gram Super EPA 2000 1000 mg Fibrates gemfibrozil 600 mg fenofibrate 67, 134, 200 mg (Tricor) 45, 145 mg (Triglide) 50, 160 mg (Antara) 43, 87, 130 mg (Lipofen) 50, 100, 150 mg Bile Acid sequestrants cholestyramine powder in packets or cans cholestyramine/light powder in packets or cans colesevelam (Welchol) 625 mg tablets colestipol (Colestid) 1G tabs, 5G granule packets Combinations ezetimibe/simvastatin (Vytorin) 10/10, 10/20, 10/40, 10/80 mg niacin/lovastatin (Advicor) 500/20, 1000/10 mg SR niacin extended release/simvastatin 500/20 mg, 750/20 mg, 1000/20 mg (Simcor) amlodipine/atorvastatin (Caduet) 2.5/10 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80 10/10, 10/20, 10/40, 10/80 mg aspirin buffered/pravastatin 81/20, 81/40, 81/80, 325/20, 325/40, 325/80 mg (Pravigard PAC) Resources Most medical groups have a provider experienced at treating patients with difficult to manage dyslipidemia. Please consult regional facilities and providers for additional resources in your area. For specialty consultations or additional assistance, contact the UW Hospital and Clinics Preventive Cardiology program. University of Wisconsin Hospital and Clinics Phone 608-263-1530 Preventive Cardiology Program 608-263-7420 600 N. Highland Avenue Madison, WI 53792 For additional nutrition information contact the UW Health Nutrition Center at 608-287-2780, or one of the UW Health Outpatient Nutrition Clinics: UW Hospital 608-263-4360, West Clinic at 608-262-9181, East Clinic at 608-265-7405 or University Station at 608-263-7772. Consult local facilities and providers for additional resources in your area. National Cholesterol Education Program http://www.nhlbi.nih.gov/guidelines/cholesterol/ Useful patient and physician materials including on-line and downloadable risk calculators2 for desktop computers and palm computers. American Heart Association http://www.americanheart.org Resources for patients and professionals. American Dietetics Association http://www.eatright.org/nuresources.html Resources for patients and professionals on healthy diets. 2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults 18 Years Old - May 2008 – Page 9
  • 11. References • rundy SM, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment G Panel III Guidelines. Circulation 2004; 110: 227-239 • xecutive Summary of the 3rd Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, E Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497. • Grundy SM. Role of therapy with “statins” in patients with hypertriglyceridemia. Am J Cardiol 1998;81:1B-6B. • tone NJ, Blum CB, Winslow E. Management of lipids in clinical practice. 5th ed. Caddo, OK, Professional Communications, S Inc., 2005. • annon CP, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. NEJM 2004; C 350: 1495-1504. • allantyne CM, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin B in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study. American Heart Journal 2005; 149: 464-473. • McBride PE, Stein JH. Contemporary Diagnosis and management in Preventative Cardiology. Handbooks in Health Care, Newton, PA, 2006. Acknowledgements Disclosures University of Wisconsin Medical Foundation, University of Wisconsin Hospitals and Clinics, Meriter Hospital, Physicians Plus Insurance Corporation, Unity Health Insurance and Group Health Cooperative have cooperated in the revision of these lipid management guidelines. James Stein, MD and Patrick McBride, MD, MPH, both from the UW Preventive Cardiology Program and the University of Wisconsin School of Medicine and Public Health, led the revision efforts. Additional contributing task force members include: Jessica Bartell, MD; Fred Brodsky, MD; Maggie Dugan, NP; Lawrence Fleming, MD, MBA; Derek Hubbard, MD; Pam Kittleson, RPh; and Jennifer Schauer, PharmD. Please direct questions, comments and suggestions regarding these guidelines to Pam Kittleson, RPh, UWMF provider education pharmacist, at pamela.kittleson@uwmf.wisc.edu. Reviewed and updated February 2008 Scheduled for reconsideration second quarter 2010 Disclosures These faculty have disclosed the following: • ames Stein, MD, Professor of Medicine, Division of Cardiovascular Medicine, and Director of the Preventive Cardiology J Program, University of Wisconsin School of Medicine and Public Health Scientific Consultant: Merck, Pfizer, Schering-Plough Research/training grants: Bristol-Myers Squibb, Kos, Sanofi-Aventis, Takeda Speaker's bureau: All honoraria donated directly to charity • atrick McBride, MD, Professor of Medicine and Family Medicine, Division of Cardiovascular Medicine, University of P Wisconsin School of Medicine and Public Health Consultant: Johnson Johnson, Reliant 2008 Guidelines for the Diagnosis and Management of Dyslipidemias for Adults 18 Years Old - May 2008 – Page 10